Hydroxychloroquine After Complete Heart Block Diagnosis and Relationship to Patient Outcomes: A Descriptive Cohort Study
- 10 December 2025
- journal article
- Published by Wiley in Prenatal Diagnosis
- Vol. 46 (1) , 94-104
Abstract
Objective: Congenital complete heart block (CHB) carries significant morbidity and mortality. Maternal Hydroxychloroquine may prevent CHB in subsequent pregnancies. No studies have explored the benefit of Hydroxychloroquine initiated after the diagnosis of CHB. We hypothesized fetuses exposed to Hydroxychloroquine, even after CHB diagnosis, will have improved outcomes using time to pacemaker placement as the primary outcome. Methods: A single‐center retrospective study was conducted on patients with CHB secondary to maternal anti‐SSA antibodies approximately 2005–2024. Results: All patients ( n = 42) received prenatal Dexamethasone. Twenty‐four patients received prenatal Dexamethasone + Hydroxychloroquine; nine were started on Hydroxychloroquine prior to CHB diagnosis, while 15 were started on Hydroxychloroquine after diagnosis. Fetal hydrops occurred more in patients treated with Dexamethasone alone ( p = 0.004). Oligohydramnios occurred more in patients on Dexamethasone + Hydroxychloroquine ( p = 0.003). There was a higher likelihood of pacing at birth in the Dexamethasone only group ( p = 0.045), but no further significant differences in timing to pacemaker placement. Long‐term survival was similar. Conclusion: Increased rates of hydrops fetalis and the need for pacing at birth in the Dexamethasone only group suggest a possible positive effect of Hydroxychloroquine in utero, even if administered after the diagnosis of CHB. This study is limited by the small sample size and the inability to control for covariates. Further multicenter studies would help explore whether adjunctive treatment with Hydroxychloroquine improves outcomes, even when initiated after CHB diagnosis.Keywords
This publication has 17 references indexed in Scilit:
- NAFTNet retrospective report on the treatment of anti-Ro/SSA mediated fetal heart block with dexamethasoneThe Journal of Maternal-Fetal & Neonatal Medicine, 2022
- Birth Outcomes in Women Who Have Taken Hydroxycholoroquine During Pregnancy: A Prospective Cohort StudyArthritis & Rheumatology, 2021
- Maternal exposure to hydroxychloroquine and birth defectsBirth Defects Research, 2021
- Hydroxychloroquine early in pregnancy and risk of birth defectsAmerican Journal of Obstetrics and Gynecology, 2021
- Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive MothersJACC, 2020
- Prenatal exposure to antimalarials decreases the risk of cardiac but not non-cardiac neonatal lupus: a single-centre cohort studyRheumatology, 2017
- Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquineAnnals of the Rheumatic Diseases, 2010
- Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open‐label clinical trialArthritis & Rheumatism, 2010
- Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational studyArthritis & Rheumatism, 2010
- Atrial and Ventricular Rate Response and Patterns of Heart Rate Acceleration during Maternal–Fetal Terbutaline Treatment of Fetal Complete Heart BlockThe American Journal of Cardiology, 2007